Multidisciplinary Evaluation and a Genome-wide Analysis in a Cohort of Idiopathic Short Stature Patients
- Conditions
- Idiopathic Short Stature
- Interventions
- Diagnostic Test: Evaluation of the prevalence of truly (authentified) idiopathic short stature after multidisciplinary clinico-radiological evaluationProcedure: analysis in a multidisciplinary consultation meeting via a secure platform (ShareConfrère) for evaluation by multidisciplinary teamGenetic: Whole genome analysis for authentified idiopathic short stature
- Registration Number
- NCT05858606
- Lead Sponsor
- University Hospital, Montpellier
- Brief Summary
Our trial aims to evaluate the prevalence of idiopathic short stature among children whose growth is above -2,5SD (AFPA- CRESS/Inserm -CompuGroup Medical 2018 curve) or above -2SD of the parental target size (taking child gender into account), after exclusion of classical pediatric and endocrinologic pathologies, and to evaluate the prevalence of monogenic causes of idiopathic short stature. We propose to perform a two-step study. The first one consists in a standardized multidisciplinary clinico-radiological evaluation of those children to evaluate the real prevalence of idiopathic short stature (ISS) among these patients. The second step consists in performing a whole genome sequencing analysis in the 30 first patients for whom the diagnosis of ISS is confirmed.
- Detailed Description
Detailed description: Establishing the etiological diagnosis of short stature is an important step to guide the therapeutic management of patients and to propose appropriate genetic counseling. Short stature can be a symptom of many pathologies. However, in the majority of cases (80%), no specific etiology is found during a pediatric clinical investigation. In this case, the diagnosis of "idiopathic" short stature is performed. However, the diagnostic and therapeutic management of short stature after exclusion of classical pediatric causes is extremely heterogeneous and there are currently no consensual recommendations. We could therefore expect to have a much higher proportion of diagnosed patients with more standardized procedures both clinical and genetic. Additionally, in recent years, new methods of genetic investigation (gene panel, whole exome or whole genome sequencing analysis) have made it possible to identify many genetic variants associated with apparently isolated short stature. So far, none of the publications reporting next-generation sequencing analysis have focused on patients with authentic idiopathic short stature, i.e. without associated bone anomalies or syndromic features, and are often focused on only a subset of target genes.
Our trial aims at estimating the prevalence of idiopathic short stature among children whose growth is above -2,5SD (AFPA- CRESS/Inserm -CompuGroup Medical 2018 curve) or above -2SD of the parental target size, after exclusion of classical pediatric and endocrinologic pathologies, and to evaluate the prevalence of monogenic causes of idiopathic short stature. We propose to perform a two-step study. The first one consists in a multidisciplinary clinico-radiological evaluation of those children to evaluate the real prevalence of idiopathic short stature (ISS) among these patients. The second step consists in performing a whole genome sequencing analysis in the 30 first patients for whom the diagnosis of authentic ISS is confirmed.
All patients will have:
* a pre-inclusion visit
* an inclusion visit after which the multidisciplinary clinico-radiological evaluation will be held
This analysis will assign patients to the diagnosis of either:
1. non-idiopathic short stature (diagnosis of constitutional bone disease or syndromic disorder)
2. authentic idiopathic short stature
A teleconsultation (1) to explain to the parents the conclusions of the multidisciplinary clinico-radiological evaluation.
This teleconsultation will be followed for all patients in the "non-idiopathic short stature" group, by a visit to take samples for genetic analysis in the context of clinical care, followed by a teleconsultation (2) to give them and explain the results
This teleconsultation will be followed for the first 30 patients in the "authentified idiopathic short stature" group, by a visit to take samples for whole genome analysis in the context of research, followed by a teleconsultation (2) to return the results.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 200
- Children aged 4 to 18 years
- 2 sexes
- Height less than -2.5DS (standard deviations of the AFPA- CRESS/Inserm -CompuGroup Medical 2018 curve) or less than -2DS of the TCP (parental target height, corresponding to the average of parental heights +6.5 cm in boys, -6.5 cm in girls)
- Normal karyotype + FISH SHOX for girls
- Previously performed:celiac disease antibodies, WBC-platelets, CRP, blood ionogram, creatinine, blood calcium, blood phosphorus, ASAT, ALAT, PAL, PTH, TSH, T4L, growth hormone test normal according to the standards of the laboratory of the CHU of Montpellier
- Acceptance of X-rays, in addition to those already performed as part of the care, which will not be repeated if necessary: spine front and profile, pelvis front, 1 upper limb front, 1 lower limb front F, hands and feet front
- Acceptance of photographs: whole body with underwear, face face and profile, 2 faces of hands; feet, face
- Acceptance of blood samples for the child and the 2 parents (trio)
- Consent signed by both parents
- Intellectual disability (IQ below 70)
- Cardiac, renal, digestive or cerebral malformation, cleft lip or palate, hearing or visual impairment, epilepsy
- Renal or cardiac insufficiency, digestive or chronic inflammatory pathology
- Previously established genetic diagnosis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 200 patients with idiopathic short stature, Evaluation of the prevalence of truly (authentified) idiopathic short stature after multidisciplinary clinico-radiological evaluation 200 patients with apparently idiopathic short stature, 200 patients with idiopathic short stature, analysis in a multidisciplinary consultation meeting via a secure platform (ShareConfrère) for evaluation by multidisciplinary team 200 patients with apparently idiopathic short stature, 200 patients with idiopathic short stature, Whole genome analysis for authentified idiopathic short stature 200 patients with apparently idiopathic short stature,
- Primary Outcome Measures
Name Time Method proportion of patients with authentified idiopathic short stature after multidisciplinary clinical-radiological analysis 3 years Primary endpoint:
The primary outcome is the proportion of patients with authentified idiopathic short stature after multidisciplinary clinical-radiological analysis (including geneticist, orthopedist, pediatric endocrinologist, radiologist) performed during a dedicated Multidisciplinary Consultation Meeting (MCM)
- Secondary Outcome Measures
Name Time Method Variants within the same gene identified in at least 2 patients by whole genome analysis in the group of 30 patients with authentified idiopathic short stature in whom genome analysis has been performed 3 years Rate of positivity of molecular analyses prescribed as part of the care following the PCR 3 years Rate of positivity of molecular analyses prescribed as part of the care following the PCR (positive diagnosis of pathogenic or probably pathogenic variants involved in the phenotype) for patients with non-idiopathic short stature
Type of change in management due to genome analysis results 3 years Type of change in management due to genome analysis results: initiation/withdrawal of treatment, referral to organ specialist for specific multidisciplinary management (patients with authentified idiopathic short stature/ Genome+)
Type of management modification by molecular analysis resultscare context for those with non-idiopathic short stature 3 years Type of management modification by molecular analysis results: initiation/withdrawal of treatment, referral to organ specialist for specific multidisciplinary management (patients with non-idiopathic short stature).
Rate of modification of management by the results of genome analysis 3 years Rate of modification of management by the results of genome analysis in the group of 30 patients with authentified idiopathic short stature in whom genome analysis has been performed
Rate of change in management by results of molecular analysis performed in a patient-care context for those with non-idiopathic short stature 3 years Parental satisfaction assessed via a visual analog scale (Teleconsultation (1) and (2)) 3 years Genome positivity rate 3 years Genome positivity rate (positive diagnosis of pathogenic variation (class 5, Figure 3) or probably pathogenic variation (class 4, Figure 3) variants involved in the phenotype) in the group of 30 patients with authentified idiopathic short stature patients in whom the genome analysis was performed